Proactive analyst, Daniel Appiah, discusses with Chris Rhodes his latest assessment of Open Orphan.
The company now has challenge studies running in 10 different infections/conditions with new models being developed and added all the time, including asthma and malaria models.
Its contract order book stands at over £80mln — almost three times the value a year ago.
